Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/projects/958-a-phase-1-open-label-multicenter-study-to-assess-safety-tolerability-pk-and-efficacy-of-mk-1084-as-monotherapy-and-in-combination-with-pembrolizumab-in-subjects-with-krasg12c-mutant-advanced-solid-tumors/authors